Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
1.
Am J Transplant ; 9(2): 382-8, 2009 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-19067657

RESUMEN

Islet cell transplantation can cure type 1 diabetes, but allograft rejection and recurrent autoimmunity may contribute to decreasing insulin independence over time. In this study we report the association of allograft-specific proliferative and cytokine profiles with clinical outcome. Peripheral blood mononuclear cells were obtained of 20 islet recipients. Cytokine values in mixed lymphocyte cultures (MLC) were determined using stimulator cells with graft-specific HLA class II. Qualitative and quantitative cytokine profiles were determined before and after islet transplantation, blinded from clinical outcome. Cytotoxic T Lymphocyte precursor (CTLp) assays were performed to determine HLA class I alloreactivity. Allograft-specific cytokine profiles were skewed toward a Th2 or regulatory (Treg) phenotype after transplantation in insulin-independent, but not in insulin-requiring recipients. IFNgamma/IL10 ratio and MLC proliferation decreased after transplantation in insulin-independent recipients (p = 0.006 and p = 0.01, respectively). Production of the Treg cytokine IL10 inversely correlated with proliferation in alloreactive MLC (p = 0.008) and CTLp (p = 0.005). Production of IL10 combined with low-MLC reactivity associated significantly with insulin independence. The significant correlation between allograft-specific cytokine profiles and clinical outcome may reflect the induction of immune regulation in successfully transplanted recipients. Islet donor-specific IL10 production correlates with low alloreactivity and superior islet function.


Asunto(s)
Citocinas/metabolismo , Trasplante de Islotes Pancreáticos , Islotes Pancreáticos/inmunología , Estudios de Cohortes , Diabetes Mellitus/terapia , Humanos , Prueba de Cultivo Mixto de Linfocitos , Linfocitos T Citotóxicos/inmunología , Linfocitos T Reguladores/inmunología , Trasplante Homólogo , Resultado del Tratamiento
2.
Clin Exp Immunol ; 154(3): 353-9, 2008 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-19037920

RESUMEN

Type I diabetes (T1D) is a T cell-mediated autoimmune disease characterized by loss of tolerance to islet autoantigens, leading to the destruction of insulin-producing beta cells. Peripheral tolerance to self is maintained in health through several regulatory mechanisms, including a population of CD4+CD25hi naturally occurring regulatory T cells (T(regs)), defects in which could contribute to loss of self-tolerance in patients with T1D. We have reported previously that near to T1D onset, patients demonstrate a reduced level of suppression by CD4+CD25hi T(regs) of autologous CD4+CD25- responder cells. Here we demonstrate that this defective regulation is also present in subjects with long-standing T1D (> 3 years duration; P = 0.009). No difference was observed in forkhead box P3 or CD127 expression on CD4+CD25hi T cells in patients with T1D that could account for this loss of suppression. Cross-over co-culture assays demonstrate a relative resistance to CD4+CD25hi T(reg)-mediated suppression within the CD4+CD25- T cells in all patients tested (P = 0.002), while there appears to be heterogeneity in the functional ability of CD4+CD25hi T(regs) from patients. In conclusion, this work demonstrates that defective regulation is a feature of T1D regardless of disease duration and that an impaired ability of responder T cells to be suppressed contributes to this defect.


Asunto(s)
Diabetes Mellitus Tipo 1/inmunología , Autotolerancia/inmunología , Linfocitos T Reguladores/inmunología , Adulto , Recuento de Linfocito CD4 , Proliferación Celular , Células Cultivadas , Técnicas de Cocultivo , Factores de Transcripción Forkhead/sangre , Humanos , Subunidad alfa del Receptor de Interleucina-2/sangre , Subunidad alfa del Receptor de Interleucina-7/sangre , Activación de Linfocitos/inmunología , Persona de Mediana Edad
3.
Diabetologia ; 46(4): 496-503, 2003 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-12684749

RESUMEN

AIMS/HYPOTHESIS: Presentation of peptide epitopes derived from beta-cell autoantigens, such as insulin and its precursor molecules, by MHC class II molecules to autoreactive T-cells is believed to play a role in the development of Type 1 diabetes. However, little is known about the interaction between peptides of (prepro)insulin and MHC class II molecules permissive and protective for Type 1 diabetes. In this study therefore, peptides spanning the human preproinsulin sequence were assessed for their binding characteristics to Type 1 diabetes-protective and -permissive HLA molecules. METHODS: HLA-DR2, -DQ6.2 (Type 1 diabetes-protective) and HLA-DR4, -DQ8 (Type 1 diabetes permissive) molecule binding affinity for overlapping synthetic 20mer peptides spanning human preproinsulin was measured in a direct competition binding assay against a biotinylated indicator peptide. RESULTS: All HLA molecules tested showed similarity in their binding characteristics across the preproinsulin molecule, with regions of the insulin A-chain showing the highest affinity and C-peptide regions the lowest affinity for all HLA molecules tested. Furthermore, an insulin peptide implicated as a major CD4+ T-cell target in disease pathogenesis (B9-23) had high affinity binding to both protective and permissive HLA molecules but did not represent the highest affinity region of (prepro)insulin identified in either case. CONCLUSION/INTERPRETATION: The results suggest that peptide binding affinity alone is unlikely to be the major determinant of disease susceptibility in relation to interactions between (prepro)insulin epitopes and HLA molecules. The identification of epitopes derived from beta-cell autoantigens that bind promiscuously to diabetes-permissive HLA molecules could be important in the design of peptide-based immunotherapeutic strategies for the prevention of Type 1 diabetes.


Asunto(s)
Diabetes Mellitus Tipo 1/metabolismo , Antígenos de Histocompatibilidad Clase II/metabolismo , Proinsulina/metabolismo , Unión Proteica/fisiología , Diabetes Mellitus Tipo 1/inmunología , Susceptibilidad a Enfermedades , Antígenos HLA-DQ/inmunología , Antígenos HLA-DQ/metabolismo , Antígeno HLA-DR2/inmunología , Antígeno HLA-DR2/metabolismo , Antígeno HLA-DR4/inmunología , Antígeno HLA-DR4/metabolismo , Antígenos de Histocompatibilidad Clase II/inmunología , Humanos , Proinsulina/inmunología , Unión Proteica/inmunología , Precursores de Proteínas/inmunología
SELECCIÓN DE REFERENCIAS
Detalles de la búsqueda